Rajesh B. Parekh - May 19, 2021 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Role: Director
Signature: /s/ Neil S. Belloff, Attorney-in-Fact
Stock symbol: ELOX
Transactions as of: May 19, 2021
Transactions value $: $0
Form type: 4
Date filed: 5/20/2021, 04:11 PM
Previous filing: May 17, 2021
Next filing: Oct 28, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELOX	Stock Option (Right to Buy)	Award	$0	+3.33K		$0.00	3.33K	May 19, 2021	Common Stock	3.33K	$1.48	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.
F2	The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP.

Content

The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date.

The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP.